US FDA Highlights Work To Advance Predictive Toxicology, Non-Animal Testing For Cosmetics
The FDA’s cosmetics office is exploring integrated testing strategies to identify potential skin sensitizers without use of animals, as well as use of in vitro assays to evaluate cosmetic ingredients’ dermal penetration potential. Meanwhile, CFSAN is testing the effects of substances on gene expression in collaboration with other federal agencies as part of Tox21-Phase III.
You may also be interested in...
The US FDA is highly engaged in the areas of predictive toxicology and alternative methods to phase out cosmetic animal testing, including evaluation of a 3D-bioprinted human skin model for in vitro permeation testing. However, continued progress is “critically needed” to make feasible the ban on cosmetic animal testing envisioned by US lawmakers, agency leadership suggests.
Independent Beauty Association president Ken Marenus discusses the trade group’s vision for modern, proportionate cosmetics regulation and forces at work that could undermine progress and endanger small businesses.
The proposed bill in the US Senate could be seen as slightly friendlier to the cosmetics industry when it comes to continued use of animal testing data in limited, exempted contexts, compared with similar state laws enacted of late. But the federal bill includes stiffer penalties, addresses “cruelty free” labeling, and seeks to spur FDA acceptance of alternative test methods, a key objective for stakeholders overall.